These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 23532330)
1. Focus issue: From genomic mutations to oncogenic pathways. Gough NR Sci Signal; 2013 Mar; 6(268):eg3. PubMed ID: 23532330 [TBL] [Abstract][Full Text] [Related]
2. Cancer-related networks: a help to understand, predict and change malignant transformation. Csermely P; Korcsmáros T Semin Cancer Biol; 2013 Aug; 23(4):209-12. PubMed ID: 23831276 [TBL] [Abstract][Full Text] [Related]
3. Deciphering the genetic landscape of cancer--from genes to pathways. Copeland NG; Jenkins NA Trends Genet; 2009 Oct; 25(10):455-62. PubMed ID: 19818523 [TBL] [Abstract][Full Text] [Related]
5. Changing mutational and adaptive landscapes and the genesis of cancer. Liggett LA; DeGregori J Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050 [TBL] [Abstract][Full Text] [Related]
6. [Molecular cancer biology--from research to clinical practice]. Nielsen FC Ugeskr Laeger; 2003 Feb; 165(9):897-900. PubMed ID: 12661511 [TBL] [Abstract][Full Text] [Related]
7. Functional genomics to explore cancer cell vulnerabilities. Kahle KT; Kozono D; Ng K; Hsieh G; Zinn PO; Nitta M; Chen CC Neurosurg Focus; 2010 Jan; 28(1):E5. PubMed ID: 20043720 [TBL] [Abstract][Full Text] [Related]
8. Big science: The cancer genome challenge. Ledford H Nature; 2010 Apr; 464(7291):972-4. PubMed ID: 20393534 [No Abstract] [Full Text] [Related]
9. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Workman P Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933 [TBL] [Abstract][Full Text] [Related]
10. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Wilting RH; Dannenberg JH Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866 [TBL] [Abstract][Full Text] [Related]
12. [Cancer genetics. A review of oncological molecular biology seen in relation to the human genome]. Gerdes AM Ugeskr Laeger; 2002 May; 164(22):2865-71. PubMed ID: 12082811 [TBL] [Abstract][Full Text] [Related]
13. [Molecular (de)regulation and cancer: new therapeutic strategies]. Boulukos KE; Carlotti F; Pognonec P Bull Cancer; 2001 Apr; 88(4):363-8. PubMed ID: 11371370 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893 [TBL] [Abstract][Full Text] [Related]
15. Cell death and survival signaling in oncogenesis. Fulda S Klin Padiatr; 2010 Nov; 222(6):340-4. PubMed ID: 20862627 [TBL] [Abstract][Full Text] [Related]
16. Understanding genomic alterations in cancer genomes using an integrative network approach. Wang E Cancer Lett; 2013 Nov; 340(2):261-9. PubMed ID: 23266571 [TBL] [Abstract][Full Text] [Related]